Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Chemotherapy"" wg kryterium: Temat


Starter badań:

Tytuł :
Survival Response of Patients With Gastric Cancer Treated With Regional Arterial-Perfusion Chemotherapy Is Correlated With Borrmann Classification.
Autorzy :
Ma YE; College of Medical Imaging, Xuzhou Medical University, Xuzhou, P.R. China.
Liang X; College of Medical Imaging, Xuzhou Medical University, Xuzhou, P.R. China.
Liu LI; Department of Interventional Therapy, Department of Radiology, Jinling Hospital, Nanjing, P.R. China.
Gao D; Department of Interventional Therapy, Department of Radiology, Jinling Hospital, Nanjing, P.R. China.
Yang T; College of Medical Imaging, Xuzhou Medical University, Xuzhou, P.R. China.; Department of Interventional Therapy, Department of Radiology, Jinling Hospital, Nanjing, P.R. China.
Hoffman RM; AntiCancer Inc., San Diego, CA, U.S.A.; Department of Surgery, UCSD, San Diego, CA, U.S.A.
Xu J; College of Medical Imaging, Xuzhou Medical University, Xuzhou, P.R. China; .; Department of Interventional Therapy, Department of Radiology, Jinling Hospital, Nanjing, P.R. China.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Nov; Vol. 41 (11), pp. 5507-5515.
Typ publikacji :
Journal Article
MeSH Terms :
Chemotherapy, Cancer, Regional Perfusion*/adverse effects
Chemotherapy, Cancer, Regional Perfusion*/mortality
Neoadjuvant Therapy*/adverse effects
Neoadjuvant Therapy*/mortality
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Stomach Neoplasms/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant ; Female ; Gastrectomy ; Humans ; Lymph Node Excision ; Male ; Margins of Excision ; Middle Aged ; Neoplasm Staging ; Retrospective Studies ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Peritoneal Spread of Low-grade Appendiceal Tumours - 2 Days of Early Postoperative Intra-peritoneal Chemotherapy Are Enough.
Autorzy :
Rao A; Department of Surgery, University of New South Wales, St George Hospital, Kogarah, NSW, Australia.
Mui J; Department of Surgery, University of New South Wales, St George Hospital, Kogarah, NSW, Australia.
Barat S; Department of Surgery, University of New South Wales, St George Hospital, Kogarah, NSW, Australia.
Matar AA; Department of Surgery, University of New South Wales, St George Hospital, Kogarah, NSW, Australia.
Alzahrani N; Department of Surgery, University of New South Wales, St George Hospital, Kogarah, NSW, Australia.; College of Medicine, Imam Muhammad Ibn Saud Islamic University, Riyadh, Kingdom of Saudi Arabia.; Department of Surgery, National Guard Health Affairs, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia.
Morris DL; Department of Surgery, University of New South Wales, St George Hospital, Kogarah, NSW, Australia; .
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Nov; Vol. 41 (11), pp. 5569-5575.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Cytoreduction Surgical Procedures*/adverse effects
Cytoreduction Surgical Procedures*/mortality
Hyperthermic Intraperitoneal Chemotherapy*/adverse effects
Hyperthermic Intraperitoneal Chemotherapy*/mortality
Appendiceal Neoplasms/*therapy
Peritoneal Neoplasms/*therapy
Pseudomyxoma Peritonei/*therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Appendiceal Neoplasms/mortality ; Appendiceal Neoplasms/pathology ; Chemotherapy, Adjuvant ; Databases, Factual ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Peritoneal Neoplasms/mortality ; Peritoneal Neoplasms/secondary ; Pseudomyxoma Peritonei/mortality ; Pseudomyxoma Peritonei/secondary ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer.
Autorzy :
Manning-Geist BL; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA. .; Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. .
Sullivan MW; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.; Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Sarda V; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.
Gockley AA; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.
Del Carmen MG; Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Matulonis U; Dana-Farber Cancer Institute, Boston, MA, USA.
Growdon WB; Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Horowitz NS; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.
Berkowitz RS; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.
Clark RM; Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Worley MJ Jr; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.
Pokaż więcej
Źródło :
Annals of surgical oncology [Ann Surg Oncol] 2021 Oct; Vol. 28 (11), pp. 6705-6713. Date of Electronic Publication: 2021 Mar 08.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/pathology
Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/pathology ; Chemotherapy, Adjuvant ; Cytoreduction Surgical Procedures ; Disease-Free Survival ; Female ; Humans ; Infusions, Parenteral ; Neoplasm Staging ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Autorzy :
Jaramillo S; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany. .
Krisam J; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Le Cornet L; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.
Kratzmann M; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.
Baumann L; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Sauer T; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Crysandt M; Department of Medicine IV, Aachen University Hospital, Aachen, Germany.
Rank A; Department of Medicine II, Augsburg University Hospital, Augsburg, Germany.
Behringer D; Department of Hematology, Oncology and Palliative Medicine, Augusta Hospital Bochum, Bochum, Germany.
Teichmann L; Department of Medicine and Polyclinic III, Bonn University Hospital, Bonn, Germany.
Görner M; Department of Hematology, Oncology and Palliative Medicine, Community Hospital Bielefeld, Bielefeld, Germany.
Trappe RU; Department of Medicine II, Prot. Diaconal Hospital Bremen, Bremen, Germany.
Röllig C; Department of Internal Medicine I, TU Dresden University Hospital, Dresden, Germany.
Krause S; Department of Medicine V, Erlangen University Hospital, Erlangen, Germany.
Hanoun M; Department of Hematology, Essen University Hospital, Essen, Germany.
Hopfer O; Department of Medicine I, Hospital Frankfurt (Oder), Frankfurt (Oder), Germany.
Held G; Department of Internal Medicine I, Westpfalz Hospital Kaiserslautern, Kaiserslautern, Germany.
Buske S; Department of Medicine II, Community Hospital Kiel, Kiel, Germany.
Fransecky L; Department of Internal Medicine II, Schleswig-Holstein University Hospital Kiel, Kiel, Germany.
Kayser S; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.; Department of Medicine I - Hematology and Cell Therapy, Leipzig University Hospital, Leipzig, Germany.
Schliemann C; Department of Medicine A, Münster University Hospital, Münster, Germany.
Schaefer-Eckart K; Department of Internal Medicine V, North Hospital Nürnberg, Nürnberg, Germany.
Al-Fareh Y; Department of Hematology and Oncology, St. Josef Brothers' Hospital Paderborn, Paderborn, Germany.
Schubert J; Department of Internal Medicine II, Elbland Hospital Riesa, Riesa, Germany.
Geer T; Department of Medicine II, Diaconal Hospital Schwäbisch-Hall, Schwäbisch Hall, Germany.
Kaufmann M; Department of Hematology, Oncology and Palliative Medicine, Robert-Bosch Hospital Stuttgart, Stuttgart, Germany.
Brecht A; Department of Internal Medicine II, Helios Dr. Horst Schmidt Hospital Wiesbaden, Wiesbaden, Germany.
Niemann D; Department of Internal Medicine, Hematology, Oncology and Palliative Medicine, Prot. Monastery Hospital St. Jakob Koblenz, Koblenz, Germany.
Kieser M; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Bornhäuser M; Department of Internal Medicine I, TU Dresden University Hospital, Dresden, Germany.
Platzbecker U; Department of Medicine I - Hematology and Cell Therapy, Leipzig University Hospital, Leipzig, Germany.
Serve H; Department of Hematology/Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany.
Baldus CD; Department of Internal Medicine II, Schleswig-Holstein University Hospital Kiel, Kiel, Germany.
Müller-Tidow C; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Schlenk RF; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.
Pokaż więcej
Źródło :
Trials [Trials] 2021 Nov 03; Vol. 22 (1), pp. 765. Date of Electronic Publication: 2021 Nov 03.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Induction Chemotherapy*
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Aged ; Aminoglycosides/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Benzimidazoles ; Gemtuzumab ; Humans ; Middle Aged ; Phenylurea Compounds
Czasopismo naukowe
Tytuł :
Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer.
Autorzy :
Nozawa H; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kawai K; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Sasaki K; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Murono K; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Emoto S; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yokoyama Y; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Abe S; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kishikawa J; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nagai Y; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Sonoda H; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Anzai H; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Ozawa T; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Ishihara S; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Pokaż więcej
Źródło :
International journal of clinical practice [Int J Clin Pract] 2021 Nov; Vol. 75 (11), pp. e14863. Date of Electronic Publication: 2021 Sep 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*
Colorectal Neoplasms*/drug therapy
Capecitabine/therapeutic use ; Chemotherapy, Adjuvant ; Female ; Fluorouracil/therapeutic use ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Oxaliplatin/therapeutic use
Czasopismo naukowe
Tytuł :
Use of wide-spectrum antimicrobials with blood culture tests during chemotherapy as an accurate marker of febrile neutropenia in the DPC database: A validation study.
Autorzy :
Matsuda K; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. Electronic address: .
Ise M; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Shimura A; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Honda A; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Masamoto Y; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Jo T; Division of Health Service Promotion, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Yasunaga H; Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Kurokawa M; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan; Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Pokaż więcej
Źródło :
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy [J Infect Chemother] 2021 Oct; Vol. 27 (10), pp. 1541-1542. Date of Electronic Publication: 2021 Jul 20.
Typ publikacji :
Letter
MeSH Terms :
Anti-Infective Agents*
Chemotherapy-Induced Febrile Neutropenia*
Febrile Neutropenia*/diagnosis
Febrile Neutropenia*/drug therapy
Antineoplastic Combined Chemotherapy Protocols ; Blood Culture ; Humans ; Vincristine
Opinia redakcyjna
Tytuł :
Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Autorzy :
Chen FP; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China.
Luo YS; Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou, 510045, Guangdong, China.
Chen K; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China.
Li JY; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China.
Huo LQ; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China.
Shi L; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China.
Ou-Yang Y; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China.
Cao XP; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Jul; Vol. 151, pp. 63-71. Date of Electronic Publication: 2021 May 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Induction Chemotherapy*/adverse effects
Induction Chemotherapy*/mortality
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cell-Free Nucleic Acids/*blood
DNA, Viral/*blood
Epstein-Barr Virus Infections/*virology
Herpesvirus 4, Human/*genetics
Nasopharyngeal Carcinoma/*drug therapy
Nasopharyngeal Neoplasms/*drug therapy
Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemoradiotherapy ; Databases, Factual ; Disease-Free Survival ; Epstein-Barr Virus Infections/blood ; Epstein-Barr Virus Infections/mortality ; Female ; Humans ; Male ; Middle Aged ; Nasopharyngeal Carcinoma/mortality ; Nasopharyngeal Carcinoma/secondary ; Nasopharyngeal Carcinoma/virology ; Nasopharyngeal Neoplasms/mortality ; Nasopharyngeal Neoplasms/pathology ; Nasopharyngeal Neoplasms/virology ; Neoplasm Staging ; Progression-Free Survival ; Radiotherapy, Intensity-Modulated ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Time Factors ; Viral Load
Czasopismo naukowe
Tytuł :
Pegteograstim prophylaxis for chemotherapy-induced neutropenia and febrile neutropenia: a prospective, observational, postmarketing surveillance study in Korea.
Autorzy :
Cheon J; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunwhandoro, Dong-gu, Ulsan, 44033, Republic of Korea.
Im HS; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunwhandoro, Dong-gu, Ulsan, 44033, Republic of Korea.
Shin HJ; Division of Hematology-Oncology, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea.
Kim I; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Lee WS; Department of Hematology and Oncology, Inje University Busan Paik Hospital, Busan, Republic of Korea.
Lee KH; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Park SK; Department of Hematology and Oncology, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea.
Kim MK; Department of Hematology and Oncology, Yeungnam University College of Medicine, Deagu, Republic of Korea.
Choi UJ; Department of Hematology and Oncology, Wonkwang University Hospital, Iksan, Republic of Korea.
Kim JH; Department of Hematology and Oncology, Kangnam Sacred-Heart Hospital, Seoul, Republic of Korea.
Lee I; Department of Hematology and Oncology, Catholic Kwandong University International ST. Mary's Hospital, Gangneung, Republic of Korea.
Jo JC; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunwhandoro, Dong-gu, Ulsan, 44033, Republic of Korea. .
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2021 Sep; Vol. 29 (9), pp. 5383-5390. Date of Electronic Publication: 2021 Mar 08.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Breast Neoplasms*/drug therapy
Chemotherapy-Induced Febrile Neutropenia*/epidemiology
Chemotherapy-Induced Febrile Neutropenia*/prevention & control
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/adverse effects ; Doxorubicin/therapeutic use ; Female ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Male ; Middle Aged ; Prospective Studies ; Republic of Korea ; Young Adult
Czasopismo naukowe
Tytuł :
Assessment of different induction chemotherapy regimens in locally advanced nasopharyngeal carcinoma: Meta-analysis.
Autorzy :
Guan H; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
He Y; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Su Y; West China Hospital, Sichuan University, Chengdu, China.
Wei Z; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Liu Z; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Wang J; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
He L; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Mu X; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Li R; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Hu X; Department of Nursing, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Peng X; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Pokaż więcej
Źródło :
Head & neck [Head Neck] 2021 Aug; Vol. 43 (8), pp. 2332-2341. Date of Electronic Publication: 2021 Mar 31.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms :
Induction Chemotherapy*
Nasopharyngeal Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bayes Theorem ; Chemoradiotherapy ; Cisplatin/therapeutic use ; Humans ; Nasopharyngeal Carcinoma/drug therapy
Czasopismo naukowe
Tytuł :
Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203.
Autorzy :
Moseley A; Public Health Sciences Division and SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Othus M; Public Health Sciences Division and SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Garcia-Manero G; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
Appelbaum FR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
Erba HP; Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.
Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Jul; Vol. 62 (7), pp. 1774-1777. Date of Electronic Publication: 2021 Feb 09.
Typ publikacji :
Letter; Research Support, N.I.H., Extramural
MeSH Terms :
Induction Chemotherapy*
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Remission Induction
Raport
Tytuł :
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
Autorzy :
Möbus V; Department of Medicine II, Hematology & Oncology, University of Frankfurt, Germany.
Lück HJ; Gynecologic Oncology Practice, Hannover, Germany.
Ladda E; Oncological Practice Neumarkt, Germany.
Klare P; MediOnko-Institute GbR, Berlin, Germany.
Schmidt M; Department of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Schneeweiss A; National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany.
Grischke EM; Department of Gynecology and Obstetrics, University Clinics Tuebingen, Tuebingen, Germany.
Wachsmann G; County Hospital Böblingen, Böblingen, Germany.
Forstbauer H; Oncology Practice Network, Troisdorf, Germany.
Untch M; Department of Gynaecology and Obstetrics, Breast Cancer and Gynecologic Oncology Center, HELIOS Klinikum Berlin Buch, Germany.
Marmé F; Department of Gynaecology and Obstetrics, University Hospital Mannheim, Germany.
Blohmer JU; Breast Center Charité-University Medicine Berlin, Germany.
Jackisch C; Sana Clinic Offenbach, Germany.
Huober J; Department of Gynecology, University of Ulm, Germany.
Stickeler E; University Hospital, Aachen, Germany.
Reinisch M; Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany.
Link T; Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Sinn BV; Institute of Pathology, Charité- University Medicine Berlin, Germany.
Janni W; Department of Gynecology and Obstetrics, University Hospital, Ulm, Germany.
Denkert C; Institute of Pathology Philipps-University Marburg, Germany.
Furlanetto J; German Breast Group, Neu-Isenburg, Germany.
Engels K; Center of Pathology, Cytology and Molecular Pathology Neuss, Germany.
Solbach C; Breast Centre, University of Frankfurt, Germany.
Schmatloch S; Breast Cancer Center, Elisabeth Hospital Kassel, Germany.
Rey J; German Breast Group, Neu-Isenburg, Germany.
Burchardi N; German Breast Group, Neu-Isenburg, Germany.
Loibl S; German Breast Group, Neu-Isenburg, Germany. Electronic address: .
Pokaż więcej
Corporate Authors :
GBG and AGO-B
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Oct; Vol. 156, pp. 138-148. Date of Electronic Publication: 2021 Aug 24.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Neoadjuvant Therapy*/adverse effects
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Breast Neoplasms/*drug therapy
Carcinoma, Ductal, Breast/*drug therapy
Carcinoma, Intraductal, Noninfiltrating/*drug therapy
Carcinoma, Lobular/*drug therapy
Adolescent ; Adult ; Aged ; Albumins/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Carcinoma, Ductal, Breast/mortality ; Carcinoma, Ductal, Breast/pathology ; Carcinoma, Intraductal, Noninfiltrating/mortality ; Carcinoma, Intraductal, Noninfiltrating/pathology ; Carcinoma, Lobular/mortality ; Carcinoma, Lobular/pathology ; Chemotherapy, Adjuvant ; Cyclophosphamide/administration & dosage ; Disease-Free Survival ; Docetaxel/administration & dosage ; Epirubicin/administration & dosage ; Female ; Germany ; Humans ; Middle Aged ; Paclitaxel/administration & dosage ; Prospective Studies ; Risk Assessment ; Risk Factors ; Time Factors ; Young Adult
Czasopismo naukowe
Tytuł :
Postoperative Pancreatic Fistula After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Update on Incidence, Risk Factors, Management, and Clinical Sequelae in 1,141 Patients.
Autorzy :
Matar A; Department of Surgery, St George Hospital, Sydney, NSW, Australia.; University of Sydney, Sydney, NSW, Australia.
Meares T; Department of Surgery, St George Hospital, Sydney, NSW, Australia.; University of Sydney, Sydney, NSW, Australia.
Fisher OM; Department of Surgery, St George Hospital, Sydney, NSW, Australia.; University of New South Wales, Sydney, NSW, Australia.; University of Notre Dame, Sydney, NSW, Australia.
Gauci C; Department of Surgery, St George Hospital, Sydney, NSW, Australia.; University of New South Wales, Sydney, NSW, Australia.
Rao A; Department of Surgery, St George Hospital, Sydney, NSW, Australia.
Alshahrani M; Department of Surgery, St George Hospital, Sydney, NSW, Australia.
Alzahrani N; Department of Surgery, St George Hospital, Sydney, NSW, Australia.; Department of Surgery, National Guard Health Affairs, King Abdulaziz Medical City Riyadh, Riyadh, Kingdom of Saudi Arabia.
Morris DL; Department of Surgery, St George Hospital, Sydney, NSW, Australia; .; University of New South Wales, Sydney, NSW, Australia.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Nov; Vol. 41 (11), pp. 5577-5584.
Typ publikacji :
Journal Article
MeSH Terms :
Cytoreduction Surgical Procedures/*adverse effects
Hyperthermic Intraperitoneal Chemotherapy/*adverse effects
Pancreatic Fistula/*epidemiology
Peritoneal Neoplasms/*therapy
Chemotherapy, Adjuvant ; Cytoreduction Surgical Procedures/mortality ; Databases, Factual ; Female ; Humans ; Hyperthermic Intraperitoneal Chemotherapy/mortality ; Incidence ; Male ; Middle Aged ; New South Wales/epidemiology ; Pancreatic Fistula/diagnosis ; Pancreatic Fistula/mortality ; Pancreatic Fistula/therapy ; Peritoneal Neoplasms/mortality ; Peritoneal Neoplasms/pathology ; Progression-Free Survival ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Time Factors
Czasopismo naukowe
Tytuł :
Far-advanced Colorectal Liver Metastases Successfully Managed With Modified ALPPS and Radiofrequency Ablation in Combination With Chemotherapy.
Autorzy :
Adachi Y; Department of Surgery, Miyazaki Nobeoka Prefectural Hospital, Nobeoka, Japan.
Yamamura K; Department of Surgery, Yamaga City Medical Center, Yamaga, Japan.
Yumoto S; Department of Surgery, Miyazaki Nobeoka Prefectural Hospital, Nobeoka, Japan.
Higashi T; Department of Surgery, Miyazaki Nobeoka Prefectural Hospital, Nobeoka, Japan.
Ishiodori H; Department of Surgery, Miyazaki Nobeoka Prefectural Hospital, Nobeoka, Japan.
Honda S; Department of Surgery, Miyazaki Nobeoka Prefectural Hospital, Nobeoka, Japan.
Hara Y; Department of Surgery, Miyazaki Nobeoka Prefectural Hospital, Nobeoka, Japan.
Matsumura K; Department of Surgery, Miyazaki Nobeoka Prefectural Hospital, Nobeoka, Japan.
Oda E; Department of Surgery, Yamaga City Medical Center, Yamaga, Japan.
Akahoshi S; Department of Surgery, Yamaga City Medical Center, Yamaga, Japan.
Yuki H; Department of Radiology, Yamaga City Medical Center, Yamaga, Japan.
Miyamoto H; Department of Medical Oncology, Yamaga City Medical Center, Kumamoto, Japan.
Doi K; Department of Surgery, Miyazaki Nobeoka Prefectural Hospital, Nobeoka, Japan.
Beppu T; Department of Surgery, Yamaga City Medical Center, Yamaga, Japan; .
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Nov; Vol. 41 (11), pp. 5855-5861.
Typ publikacji :
Case Reports
MeSH Terms :
Hepatectomy*
Neoadjuvant Therapy*
Radiofrequency Ablation*
Adenocarcinoma/*therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colorectal Neoplasms/*pathology
Liver Neoplasms/*therapy
Portal Vein/*surgery
Adenocarcinoma/diagnostic imaging ; Adenocarcinoma/secondary ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant ; Colostomy ; Humans ; Ligation ; Liver Neoplasms/diagnostic imaging ; Liver Neoplasms/secondary ; Male ; Middle Aged ; Neoplasm Staging ; Treatment Outcome
Raport
Tytuł :
Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
Autorzy :
Li Z; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing, China.
Wang Y; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing, China.
Ying X; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing, China.
Zhang L; Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.
Gao X; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing, China.
Jia Y; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing, China.
Zhang L; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing, China.
Wu A; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing, China.
Su X; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing, China.
Ji J; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing, China.
Pokaż więcej
Źródło :
Journal of surgical oncology [J Surg Oncol] 2021 Dec; Vol. 124 (8), pp. 1356-1364. Date of Electronic Publication: 2021 Sep 13.
Typ publikacji :
Journal Article
MeSH Terms :
DNA Mismatch Repair*
Adenocarcinoma/*drug therapy
Brain Neoplasms/*pathology
Chemotherapy, Adjuvant/*adverse effects
Colorectal Neoplasms/*pathology
Esophageal Neoplasms/*drug therapy
Neoadjuvant Therapy/*adverse effects
Neoplastic Syndromes, Hereditary/*pathology
Stomach Neoplasms/*drug therapy
Adenocarcinoma/pathology ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Brain Neoplasms/chemically induced ; Brain Neoplasms/genetics ; Colorectal Neoplasms/chemically induced ; Colorectal Neoplasms/genetics ; Esophageal Neoplasms/pathology ; Esophagogastric Junction/drug effects ; Female ; Follow-Up Studies ; Humans ; Male ; Microsatellite Instability ; Middle Aged ; Neoplastic Syndromes, Hereditary/chemically induced ; Neoplastic Syndromes, Hereditary/genetics ; Prognosis ; Retrospective Studies ; Stomach Neoplasms/pathology ; Survival Rate
SCR Disease Name :
Turcot syndrome
Czasopismo naukowe
Tytuł :
Efficacy and safety of cladribine addition to induction treatment of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.
Autorzy :
Pan Q; Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.
Li J; Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.
Pokaż więcej
Źródło :
Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 577-587.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cladribine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cladribine/adverse effects ; Humans ; Induction Chemotherapy ; Leukemia, Myeloid, Acute/diagnosis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Autorzy :
Moreau P; Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France. Electronic address: .
Hulin C; Bordeaux University Hospital Center, Bordeaux, France.
Perrot A; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
Arnulf B; Hematology and Oncology, Hôpital Saint Louis, APHP, Paris, France.
Belhadj K; Hôpital Henri Mondor, Creteil, France.
Benboubker L; Tours University Hospital, Hôpital de Bretonneau, Tours, France.
Béné MC; Hematology Biology, Nantes University Hospital, Nantes, France.
Zweegman S; Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Caillon H; Biochemistry Laboratory, Nantes University Hospital, Nantes, France.
Caillot D; Dijon University Hospital, Hôpital du Bocage, Dijon, France.
Corre J; Unité de Genomique du Myélome, IUC-T Oncopole, Toulouse, France.
Delforge M; Department of Hematology, University Hospital Leuven, Leuven, Belgium.
Dejoie T; Biochemistry Laboratory, Nantes University Hospital, Nantes, France.
Doyen C; Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.
Facon T; Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France.
Sonntag C; University Hospital, Hôpital Hautepierre, Strasbourg, France.
Fontan J; University Hospital Jean Minjoz, Besancon, France.
Mohty M; Hematology and Cellular Therapy Department of Saint-Antoine Hospital, Sorbonne University, Paris, France.
Jie KS; Zuyderland MC, Sittard, Netherlands.
Karlin L; Lyon University Hospital, Hematology Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
Kuhnowski F; Institut Curie Paris, Paris, France.
Lambert J; Hôpital Saint-Louis, Paris, France.
Leleu X; Poitiers University Hospital, CHU la Milétrie, Poitiers, France.
Macro M; Caen University Hospital, Caen, France.
Orsini-Piocelle F; Centre Hospitalier Annecy Genevois, Pringy, France.
Roussel M; CHU Dupuytren, Limoges, France.
Stoppa AM; Institut Paoli Calmettes, Marseille, France.
van de Donk NWCJ; Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Wuillème S; Hematology Biology, Nantes University Hospital, Nantes, France.
Broijl A; Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Touzeau C; Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France.
Tiab M; Centre Hospitalier Départemental Vendée, La Roche sur Yon, France.
Marolleau JP; Hematology Clinic, Amiens University Hospital, Amiens, France.
Meuleman N; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Vekemans MC; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Westerman M; Northwest Clinics, Alkmaar, Netherlands.
Klein SK; Meander Medical Centre, Amersfoort, Netherlands.
Levin MD; Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands.
Offner F; University Hospital Ghent, Ghent, Belgium.
Escoffre-Barbe M; Rennes University Hospital, Hôpital de Pontchaillou, Rennes, France.
Eveillard JR; Brest University Hospital, Hôpital A Morvan, Brest, France.
Garidi R; Saint-Quentin Hospital Center, Saint Quentin, France.
Ahmadi T; Genmab, Princeton, NJ, USA.
Krevvata M; Janssen Research & Development, Spring House, PA, USA.
Zhang K; Janssen Research & Development, La Jolla, CA, USA.
de Boer C; Janssen Research & Development, LLC, Leiden, Netherlands.
Vara S; Janssen Research & Development, High Wycombe, UK.
Kampfenkel T; Janssen Research & Development, LLC, Leiden, Netherlands.
Vanquickelberghe V; Janssen Research & Development, Beerse, Belgium.
Vermeulen J; Janssen Research & Development, LLC, Leiden, Netherlands.
Avet-Loiseau H; Unité de Genomique du Myélome, IUC-T Oncopole, Toulouse, France.
Sonneveld P; Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Oct; Vol. 22 (10), pp. 1378-1390. Date of Electronic Publication: 2021 Sep 13.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Stem Cell Transplantation*/adverse effects
Antibodies, Monoclonal/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bortezomib/*administration & dosage
Dexamethasone/*administration & dosage
Multiple Myeloma/*therapy
Thalidomide/*administration & dosage
Adolescent ; Adult ; Aged ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/adverse effects ; Dexamethasone/adverse effects ; Drug Administration Schedule ; Europe ; Female ; Humans ; Maintenance Chemotherapy ; Male ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiple Myeloma/mortality ; Progression-Free Survival ; Thalidomide/adverse effects ; Time Factors ; Transplantation, Autologous ; Young Adult
Czasopismo naukowe
Tytuł :
Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option.
Autorzy :
Faehling M; Klinik für Kardiologie und Pneumologie, Klinikum Esslingen, Germany. Electronic address: .
Fallscheer S; Klinik für Kardiologie und Pneumologie, Klinikum Esslingen, Germany.
Kramberg S; Klinik für Kardiologie und Pneumologie, Klinikum Esslingen, Germany.
Sträter J; Institut für Pathologie, Esslingen, Germany.
Eschmann S; MVZ Nuklearmedizin, Marienhospital, Stuttgart, Germany.
Sätzler R; Klinik für Gefäß- und Thoraxchirurgie, Klinikum Esslingen, Germany.
Heinzelmann F; MVZ Strahlentherapie, Klinikum Esslingen, Germany.
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Oct; Vol. 156, pp. 175-186. Date of Electronic Publication: 2021 Aug 27.
Typ publikacji :
Clinical Study; Comparative Study; Journal Article
MeSH Terms :
Chemoradiotherapy*/adverse effects
Chemoradiotherapy*/mortality
Neoadjuvant Therapy*/adverse effects
Neoadjuvant Therapy*/mortality
Palliative Care*
Pneumonectomy*/adverse effects
Pneumonectomy*/mortality
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Immune Checkpoint Inhibitors/*therapeutic use
Lung Neoplasms/*drug therapy
Nivolumab/*therapeutic use
Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/secondary ; Chemotherapy, Adjuvant ; Female ; Germany ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Lung Neoplasms/immunology ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Nivolumab/adverse effects ; Prospective Studies ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
Autorzy :
Sinukumar S; Jehangir Hospital, 32, Sassoon Road, Pune, Maharashtra, India. Electronic address: .
Damodaran D; Dept of Surgical Oncology, MVR, Cancer Center and Research Institute, Calicut, Kerela, India. Electronic address: .
Ray M; Dept of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, Delhi, India. Electronic address: .
Mehta S; Dept of Peritoneal Surface Oncology, Saifee Hospital, Mumbai, Maharashtra, India. Electronic address: .
Paul L; Dept of Surgical Oncology, MVR, Cancer Center and Research Institute, Calicut, Kerela, India. Electronic address: .
Bhatt A; Dept. of Surgical Oncology, Zydus Hospital, Ahmedabad, Gujarat, India. Electronic address: .
Pokaż więcej
Źródło :
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2021 Jun; Vol. 47 (6), pp. 1427-1433. Date of Electronic Publication: 2021 Jan 22.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Cytoreduction Surgical Procedures*
Hyperthermic Intraperitoneal Chemotherapy*
Brain Neoplasms/*secondary
Carcinoma, Ovarian Epithelial/*therapy
Liver Neoplasms/*secondary
Lung Neoplasms/*secondary
Neoplasm Recurrence, Local/*pathology
Ovarian Neoplasms/*therapy
Peritoneal Neoplasms/*therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Ovarian Epithelial/secondary ; Female ; Follow-Up Studies ; Humans ; Lymph Nodes/pathology ; Lymphatic Metastasis ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Neoplasm, Residual ; Ovarian Neoplasms/pathology ; Peritoneal Neoplasms/secondary ; Peritoneum/surgery ; Progression-Free Survival ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
Autorzy :
Ji ZH; Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, PR China.
Yu Y; Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, PR China.
Liu G; Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, PR China.
Zhang YB; Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, PR China.
An SL; Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, PR China.
Li B; Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, PR China.
Li XB; Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, PR China.
Yan GJ; Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, PR China.
Li Y; Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, PR China. Electronic address: .
Pokaż więcej
Źródło :
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2021 Jun; Vol. 47 (6), pp. 1411-1419. Date of Electronic Publication: 2020 Dec 01.
Typ publikacji :
Journal Article
MeSH Terms :
Cytoreduction Surgical Procedures*/adverse effects
Hyperthermic Intraperitoneal Chemotherapy*
Patient Selection*
Peritoneal Neoplasms/*pathology
Peritoneal Neoplasms/*therapy
Stomach Neoplasms/*pathology
Adult ; Aged ; Biomarkers, Tumor/blood ; Chemotherapy, Adjuvant ; Female ; Follow-Up Studies ; Humans ; Intraoperative Complications/etiology ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm, Residual ; Nomograms ; Peritoneal Neoplasms/blood ; Peritoneal Neoplasms/secondary ; Postoperative Complications/etiology ; Retrospective Studies ; Severity of Illness Index ; Stomach Neoplasms/therapy ; Survival Rate ; Time Factors ; Tumor Burden ; Young Adult
Czasopismo naukowe
Tytuł :
Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Autorzy :
Chambers LM; Division of Gynecologic Oncology, Obstetrics, Gynecology, Women's Health Institute, Cleveland Clinic, Desk A81, 9500 Euclid Avenue, Cleveland, OH 44195, United States. Electronic address: .
Yao M; Department of Qualitative Health Sciences, Cleveland Clinic, Cleveland, OH 44195, United States.
Morton M; Obstetrics, Gynecology, Women's Health Institute, Cleveland Clinic, Desk A81, 9500, United States.
Gruner M; Obstetrics, Gynecology, Women's Health Institute, Cleveland Clinic, Desk A81, 9500, United States.
Chichura A; Obstetrics, Gynecology, Women's Health Institute, Cleveland Clinic, Desk A81, 9500, United States.
Horowitz M; Division of Gynecologic Oncology, Obstetrics, Gynecology, Women's Health Institute, Cleveland Clinic, Desk A81, 9500 Euclid Avenue, Cleveland, OH 44195, United States.
Costales AB; Department of Gynecologic Oncology, Baylor College of Medicine, Houston, TX 77030, United States.
Rose PG; Division of Gynecologic Oncology, Obstetrics, Gynecology, Women's Health Institute, Cleveland Clinic, Desk A81, 9500 Euclid Avenue, Cleveland, OH 44195, United States.
Michener CM; Division of Gynecologic Oncology, Obstetrics, Gynecology, Women's Health Institute, Cleveland Clinic, Desk A81, 9500 Euclid Avenue, Cleveland, OH 44195, United States.
Debernardo R; Division of Gynecologic Oncology, Obstetrics, Gynecology, Women's Health Institute, Cleveland Clinic, Desk A81, 9500 Euclid Avenue, Cleveland, OH 44195, United States.
Pokaż więcej
Źródło :
Gynecologic oncology [Gynecol Oncol] 2021 May; Vol. 161 (2), pp. 389-395. Date of Electronic Publication: 2021 Feb 05.
Typ publikacji :
Journal Article
MeSH Terms :
Cytoreduction Surgical Procedures*
Hyperthermic Intraperitoneal Chemotherapy*
Abdominal Neoplasms/*secondary
Carcinoma, Ovarian Epithelial/*secondary
Ovarian Neoplasms/*pathology
Ovarian Neoplasms/*therapy
Pelvic Neoplasms/*secondary
Abdominal Neoplasms/diagnosis ; Abdominal Neoplasms/mortality ; Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Ovarian Epithelial/diagnosis ; Carcinoma, Ovarian Epithelial/mortality ; Carcinoma, Ovarian Epithelial/therapy ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Ovarian Neoplasms/mortality ; Pelvic Neoplasms/diagnosis ; Pelvic Neoplasms/mortality ; Registries ; Retrospective Studies ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies